More about
Severe Atopic Dermatitis
News
February 10, 2022
1 min read
Save
FDA grants priority review to Dupixent for atopic dermatitis patients 6 months to 5 years
News
January 14, 2022
1 min read
Save
FDA approves Cibinqo for moderate to severe atopic dermatitis
News
September 10, 2021
1 min read
Save
Severe atopic dermatitis associated with depression, internalizing behaviors in children
News
September 01, 2021
1 min read
Save
Methotrexate, azathioprine show comparable safety, efficacy in pediatric atopic dermatitis
News
August 27, 2021
1 min read
Save
Induction abrocitinib may prevent flare in moderate, severe atopic dermatitis
News
March 23, 2020
2 min read
Save
Abrocitinib meets co-primary endpoints in phase 3 trial
The phase 3 JADE COMPARE trial met its co-primary efficacy endpoints in adults with moderate to severe atopic dermatitis. Results from the trial, which compared the use of the JAK1 inhibitor abrocitinib with placebo, will be submitted for presentation at a future conference, according to a press release from Pfizer.
News
January 31, 2020
2 min read
Save
Baricitinib achieves primary endpoint in BREEZE-AD4, BREEZE-AD5 studies
News
August 07, 2019
1 min read
Save